



Singapore eDevelopment Names Former US Assistant Surgeon General, Dr Roscoe Moore, as Senior Scientific Adviser to its Biomedical Arm



Dr Roscoe Moore, Senior Scientific Adviser, Global BioLife Inc.

SINGAPORE, 8 January 2018 – Singapore-listed **Singapore eDevelopment Ltd (“SeD”** or the **“Group”**) announced today the appointment of Dr Roscoe M. Moore Jr. as Senior Scientific Adviser to Global BioLife Inc. (**“Global BioLife”**), and Global BioMedical Inc., both subsidiaries of SeD which have diversified into the development, research, manufacture and distribution of biomedical products and services.

A highly-regarded public health expert with a distinguished public service record under two former U.S. Presidents, Dr Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention and as Chief Epidemiologist with the Center for Devices and Radiological Health in the U.S. Food and Drug Administration. He retired with the rank of Rear Admiral which for a period of time made him the highest-ranking veterinarian of all U.S. Uniformed Services.

Dr Moore holds a Ph.D. in Epidemiology from Johns Hopkins University, a Master of Public Health degree in Epidemiology from the University of Michigan, as well as Bachelor's and Doctor of Veterinary Medicine degrees and an honorary Doctor of Science degree from Tuskegee University. A Fellow of the American College of Epidemiology and a life-member of the Delta Omega Honorary Society in Public Health, he has authored and co-authored over 100 articles on public health research, health care services, and disease transmission.

Mr Chan Heng Fai, Executive Chairman and Chief Executive Officer of SeD, said, “We are honoured that a healthcare expert of Dr Moore’s stature and experience has agreed to be our Scientific Adviser. His deep experience and networks will be invaluable as SeD develops its biomedical division globally.”

8 January 2018

Page 2 of 3

SeD in March 2017 named a senior management team for Global BioLife to spearhead advanced research of a new universal therapeutic drug platform, known as *Linebacker*, to combat a range of diseases including Alzheimer's, diabetes and cancer.

The team is led by Dr Tang Peihong, Global BioLife's Director and Chief Executive Officer who was selected as National Distinguished Expert in China's Thousand People Plan in 2012, and includes Mr Daryl Thompson, a biochemist nominated for the Nobel Prize in 2015 and 2016 for his research on pandemic technology.

Global BioMedical Inc. owns 70% of Global BioLife with the balance 20% held by Mr Daryl Thompson's GRDGS Sciences LLC ("**GRDGS**") and 10% held by Australian-listed Holista CollTech Limited ("**Holista**").

Dr Moore said, "I have been following Daryl's work in my role as Scientific Advisor of Holista. The *Linebacker* project, which seeks to offer a universal therapeutic platform based on small molecules, offers a potential game-changing breakthrough for the global pharmaceutical industry."

GRDGS has assigned its biomedical intellectual property to Global BioLife. This includes patents for its *Linebacker* platform, a synthetically universal therapeutic formula to treat and prevent pro-inflammatory derived disease. Global BioLife will leverage on the existing research findings of the natural compound, which has established therapeutic efficacy against neurologic diseases, diabetes, and viruses including rhinovirus, influenza and Ebola.

End of Release

Issued on behalf of the Company by WeR1 Consultants Pte Ltd:

Media & Investor Contact Information

WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01, Royal Group Building
Singapore 048693
Tel: (65) 6737 4844
Ian Lau, ianlau@wer1.net

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange Catalist in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology- related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor Hong Leong Finance Limited (the "Sponsor") for compliance with the relevant rules of the Singapore

8 January 2018

Page 3 of 3

Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined or approved by SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #40-01A Hong Leong Building, Singapore 048581, telephone: +65 6415-9886.